Safely targeting cancer stem cells via selective catenin coactivator antagonism

Cancer Science

Volumn 105, Issue 9, 2014, Pages 1087-1092

  Lenz, Heinz Josef ^a   Kahn, Michael ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Asymmetric; CREB binding protein; P300; Symmetric; Wnt catenin

Indexed keywords

ANTINEOPLASTIC AGENT; CATENIN; CYTOKERATIN 20; E1A ASSOCIATED P300 PROTEIN; GEMCITABINE; N BENZYL 1,2,3,4,8,9 HEXAHYDRO 6 (4 HYDROXYBENZYL) 8 (1 NAPHTHYLMETHYL) 4,7 DIOXO 2H PYRAZINO[1,2 A]PYRIMIDINE 1(6H) CARBOXAMIDE; PRI 724; SURVIVIN; UNCLASSIFIED DRUG; UVOMORULIN; BONE SIALOPROTEIN (35 62), HUMAN; BONE SIALOPROTEIN (35-62), HUMAN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; FUSED HETEROCYCLIC RINGS; ICG 001; PEPTIDE FRAGMENT; PYRIMIDINONE DERIVATIVE; SIALOGLYCOPROTEIN;

ANTINEOPLASTIC ACTIVITY; BRAIN TUMOR; BREAST TUMOR; CANCER RESEARCH; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; CHEMICAL STRUCTURE; CIRCULATING TUMOR CELL; COLON TUMOR; COLORECTAL CANCER; CONTINUOUS INFUSION; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC TRANSCRIPTION; HUMAN; HYPERBILIRUBINEMIA; LEUKEMIA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN SECONDARY STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; THERAPY RESISTANCE; UPREGULATION; WNT SIGNALING PATHWAY; ANIMAL; ASYMMETRIC; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; METABOLISM; NEOPLASM; P300; PATHOLOGY; SYMMETRIC; WNT/CATENIN;

ASYMMETRIC; CREB-BINDING PROTEIN; P300; SYMMETRIC; WNT/CATENIN;

ANIMALS; ANTINEOPLASTIC AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; CATENINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; PEPTIDE FRAGMENTS; PYRIMIDINONES; SIALOGLYCOPROTEINS; WNT SIGNALING PATHWAY;

EID: 84908185262     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12471     Document Type: Review

References (80)

1. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
2. Singh SR. Stem cell niche in tissue homeostasis, aging and cancer. Curr Med Chem 2012; 19: 5965-74.
3. Miki T, Yasuda SY, Kahn M. "Wnt/Β-catenin signaling in embryonic stem cell self-renewal and somatic cell reprogramming. Stem Cell Rev 2011; 7: 836-46.
4. Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 2010; 16: 3153-62.
5. Merchant AA, Matsui W. Targeting hedgehog - a cancer stem cell pathway. Clin Cancer Res 2010; 16: 3130-40.
6. Liu J, Sato C, Cerletti M, Wagers A. Notch signaling in the regulation of stem cell self-renewal and differentiation. Curr Top Dev Biol 2010; 92: 367-409.
7. Cohnheim J. Ueber Entzuendung und Eiterung [in German]. Path Anat Physiol Klin Med 1867; 40: 1-79.
8. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-68.
9. O'Brien CA, Kreso A, Jamieson CH. Cancer stem cells and self-renewal. Clin Cancer Res 2010; 16: 3113-20.
10. Armanios M, Greider CW. Telomerase and cancer stem cells. Cold Spring Harb Symp Quant Biol 2005; 70: 205-8.
11. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011; 17: 313-9.
12. Visvader JE, Lindeman GJ. Stem cells and cancer - the promise and puzzles. Mol Oncol 2010; 4: 369-72.
13. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007; 317: 337.
14. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-7.
15. Jamieson CH, Weissman IL, Passegué E. Chronic versus acute myelogenous leukemia: a question of self-renewal. Cancer Cell 2004; 6: 531-3.
16. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
17. Fang D, Nguyen TK, Leishear K et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65: 9328-37.
18. Dontu G, El-Ashry D, Wicha MS. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 2004; 15: 193-7.
19. Ma S, Chan KW, Hu L et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007; 132: 2542-56.
20. Li C, Heidt DG, Dalerba P et al. Identification of Pancreatic Cancer Stem Cells. Cancer Res 2007; 67: 1030-7.
21. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-10.
22. Kim YM, Ma H, Oehler V et al. The gamma catenin/CBP complex maintains survivin transcription in β-catenin deficient/depleted cancer cells. Curr Cancer Drug Targets 2011; 11: 213-25.
23. Onder TT, Gupta PB, Mani SA et al. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008; 68: 3645-54.
24. Kim K, Daniels KJ, Ha ED. Tissue-specific expression of beta-catenin in normal mesenchyme and uveal melanomas and its effect on invasiveness. Exp Cell Res 1998; 245: 79-90.
25. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011; 147: 275-92.
26. Mani SA, Guo W, Liao MJ et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-15.
27. Wagh PK, Gary JK, Zinser GM et al. β-Catenin is required for Ron receptor-induced mammary tumorigenesis. Oncogene 2011; 30: 3694-704.
28. Coluccia AM, Benati D, Dekhil H et al. SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res 2006; 66: 2279-86.
29. Ress A, Moelling K. Bcr interferes with beta-catenin-Tcf1 interaction. FEBS Lett 2006; 580: 1227-30.
30. Mazumdar J, Obrien WT, Johnson RS et al. O2 regulates stem cells through Wnt/β-catenin signalling. Nat Cell Biol 2010; 12: 1007-13.
31. Kida A, Kahn M. Hypoxia selects for a quiescent, CML stem/leukemia initiating-like population dependent on CBP/catenin transcription. Curr Mol Pharmacol 2013; 6: 204-10.
32. Chocarro-Calvo A, García-Martínez JM, Ardila-González S, De la Vieja A, García-Jiménez C. Glucose-induced β-catenin acetylation enhances Wnt signaling in cancer. Mol Cell 2013; 49: 474-86.
33. Brembeck FH, Rosário M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev 2006; 16: 51-9.
34. van Veelen W, Le NH, Helvensteijn W et al. β-catenin tyrosine 654 phosphorylation increases Wnt signalling and intestinal tumorigenesis. Gut 2011; 60: 1204-12.
35. Kawabata A. Prostaglandin E2 and pain - an update. Biol Pharm Bull 2011; 34: 1170-3.
36. Ginis , Luo Y, Miura T et al. Differences between human and mouse embryonic stem cells. Dev Biol 2004; 269: 360-80.
37. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 2004; 10: 55-63.
38. Muroyama Y, Kondoh H, Takada S. Wnt proteins promote neuronal differentiation in neural stem cell culture. Biochem Biophys Res Commun 2004; 313: 915-21.
39. Dravid G, Ye Z, Hammond H et al. Defining the role of Wnt/beta-catenin signaling in the survival, proliferation, and self-renewal of human embryonic stem cells. Stem Cells 2005; 23: 1489-501.
40. Chenn A, Walsh CA. Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. Science 2002; 297: 365-9.
41. Zehner D, Fujita Y, Hulsken J et al. beta-Catenin signals regulate cell growth and the balance between progenitor cell expansion and differentiation in the nervous system. Dev Biol 2003; 258: 406-18.
42. Hari L, Brault V, Kleber M et al. Lineage-specific requirements of beta-catenin in neural crest development. J Cell Biol 2002; 159: 867-80.
43. Kühl SJ, Kühl M. On the role of Wnt/β-catenin signaling in stem cells. Biochim Biophys Acta 2013; 1830: 2297-306.
44. Polakis P. Drugging Wnt signalling in cancer. EMBO J 2012; 31: 2737-46. Erratum in: EMBO J. 2012; 31: 3375.
45. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013; 13: 11-26.
46. Groden J, Thliveris A, Samowitz W et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991; 66: 589-600.
47. Kinzler KW, Nilbert MC, Su LK et al. Identification of FAP locus genes from chromosome 5q21. Science 1991; 253: 661-5.
48. Clements WM, Lowy AM, Grode J. Adenomatous polyposis coli/beta-catenin interaction and downstream targets: altered gene expression in gastrointestinal tumors. Clin Colorectal Cancer 2003; 3: 113-20.
49. Drier Y, Lawrence MS, Carter SL et al. Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. Genome Res 2013; 23: 228-35.
50. Rubinfeld B, Robbins O, El-Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 1997; 275: 1790-2.
51. Herr P, Hausmann G, Basler K. WNT secretion and signalling in human disease. Trends Mol Med 2012; 18: 483-93.
52. Han ZG. Functional genomic studies: insights into the pathogenesis of liver cancer. Annu Rev Genomics Hum Genet 2012; 13: 171-205.
53. Sastre-Perona A, Santisteban P. Role of the wnt pathway in thyroid cancer. Front Endocrinol (Lausanne) 2012; 3: 31.
54. Ratcliffe TA, Monk BJ, Planutis K, Holcombe RF. Wnt signaling in ovarian tumorigenesis. Int J Gynecol Cancer 2008; 18: 954-62.
55. Niehrs C. The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol 2012; 13: 767-79.
56. Le NH, Franken P, Fodde R. Tumour-stroma interactions in colorectal cancer: converging on beta-catenin activation and cancer stemness. Br J Cancer 2008; 98: 1886-93.
57. Moon RT. Wnt/beta-catenin pathway. Sci STKE 2005; 271: cm1.
58. Teo J-L, Kahn M. The Wnt signaling pathway in cellular proliferation and differentiation: a tale of two coactivators. Adv Drug Deliv Rev 2010; 62: 1149-55.
59. Angers S, Moon RT. Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol 2009; 10: 468-77.
60. Kung AL, Rebel VI, Bronson RT et al. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev 2000; 14: 272-7.
61. Yamauchi T, Oike Y, Kamon J et al. Increased insulin sensitivity despite lipodystrophy in Crebbp heterozygous mice. Nat Genet 2002; 30: 221-6.
62. Roth FJ, Shikama N, Henzen C et al. Differential role of p300 and CBP acetyltransferase during myogenesis: p300 acts upstream of MyoD and Myf5. EMBO J 2003; 2003: 5186-96.
63. McMillan M, Kahn M. Investigating Wnt signaling: a chemogenomic safari. Drug Discov Today 2005; 10: 1467-74.
64. Emami KH, Nguyen C, Ma H et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci USA 2004; 101: 12682-7.
65. Hasegawa K, Yasuda SY, Teo JL et al. Wnt signaling orchestration with a small molecule DYRK inhibitor provides long-term xeno-free human pluripotent cell expansion. Stem Cells Transl Med 2012; 1: 18-28.
66. Banerjee ER, Laflamme MA, Papayannopoulou T, Kahn M, Murry CE, Henderson WR Jr. Human embryonic stem cells differentiated to lung lineage-specific cells ameliorate pulmonary fibrosis in a xenograft transplant mouse model. PLoS ONE 2012; 7: e33165.
67. Miyabayashi T, Teo JL, Yamamoto M, McMillan M, Nguyen C, Kahn M. Wnt/beta-catenin/CBP signaling maintains long-term murine embryonic stem cell pluripotency. Proc Natl Acad Sci USA 2007; 104: 5668-73.
68. Marson A, Foreman R, Chevalier B et al. Wnt signaling promotes reprogramming of somatic cells to pluripotency. Cell Stem Cell 2008; 3: 132-5.
69. Schenke-Layland K, Nsair A, Van Handel B et al. Recapitulation of the embryonic cardiovascular progenitor cell niche. Biomaterials 2011; 2: 2748-56.
70. Wend P, Fang L, Zhu Q et al. Wnt/β-catenin signalling induces MLL to create epigenetic changes in salivary gland tumours. EMBO J 2013; 32: 1977-89.
71. Gang EJ, Hsieh YT, Pham J et al. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene 2014; 33: 2169-78.
72. He K, Xu T, Xu Y, Ring A, Kahn M, Goldkorn A. Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/β-catenin/CBP pathway. Int J Cancer 2014; 134: 43-54.
73. Henderson WR Jr, Chi EY, Ye X et al. Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci USA 2010; 107: 14309-14.
74. Hao S, He W, Li Y et al. Targeted inhibition of β-catenin/CBP signaling ameliorates renal interstitial fibrosis. J Am Soc Nephrol 2011; 22: 1642-53.
75. Sasaki T, Hwang H, Nguyen C, Kloner RA, Kahn M. The small molecule Wnt signaling modulator ICG-001 improves contractile function in chronically infarcted rat myocardium. PLoS ONE 2013; 8: e75010.
76. Cicalese A, Bonizzi G, Pasi CE et al. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 2009; 138: 1083-95.
77. Lee JY, Nakada D, Yilmaz OH et al. mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. Cell Stem Cell 2010; 7: 593-905.
78. Kahn M. Symmetric division versus asymmetric division: a tale of two coactivators. Future Med Chem 2011; 3: 1745-63.
79. Sakata T, Chen JK. Chemical 'Jekyll and Hyde's: small-molecule inhibitors of developmental signaling pathways. Chem Soc Rev 2011; 40: 4318-31.
80. El-Khoueiry AB, Ning Y, Yang D et al. A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors. J Clin Oncol 2013; 31(Suppl): Abstract 2501.